Article
Oncology
Christophe Tournigand, Thierry Andre, Emmanuel Achille, Geirard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gerard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont
Summary: In metastatic colorectal cancer, the combination of fluorouracil (FU) with leucovorin (LV) plus irinotecan or oxaliplatin showed superior efficacy compared to FU + LV alone. This study investigated two treatment sequences and found that both achieved prolonged survival with similar efficacy, but had different toxicity profiles.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Pamela Baldin, Javier Carrasco, Gabriela Beniuga, Anne Jouret-Mourin, Gauthier Demolin, Sandrine Roland, Lionel D'Hondt, Philippe Vergauwe, Daniel Van Daele, Marie Mailleux, Isabelle Sinapi, Astrid De Cuyper, Noella Bletard, Brigitte Massart, Monique Delos, Marie-Laure Castella, Aline van Maanen, Marc Van den Eynde
Summary: This prospective trial recruited 65 patients with resectable colorectal liver metastases and found that preoperative chemotherapy did not significantly affect the pathological response rate, but confirmed pathological response as an important prognostic factor.
Article
Oncology
M. Margaret Kemeny, Fengmin Zhao, Arlene A. Forastiere, Paul Catalano, Stanley R. Hamilton, Brent W. Miedema, Nancy A. Dawson, Louis M. Weiner, Brian D. Smith, Bernard A. Mason, Stephen L. Graziano, Paul B. Gilman, Alan P. Venook, Harlan A. Pinto, Robert P. Whitehead, Peter J. O'Dwyer, Al B. Benson
Summary: This phase III trial evaluated the effect of perioperative chemotherapy on overall survival for colon cancer patients. The results showed no significant difference in survival rates and disease-free survival between patients who received perioperative chemotherapy and those who did not, regardless of their stage.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Brett A. Schroeder, Margaret T. Mandelson, Vincent J. Picozzi
Summary: This study investigates the effectiveness and safety of alternating gemcitabine/nab-paclitaxel and 5-FU/leucovorin/irinotecan regimens in patients with metastatic pancreatic cancer. The results show competitive median overall survival rates and encouraging long-term survival rates. This regimen has potential for the treatment of metastatic pancreatic cancer.
Article
Oncology
In Sil Choi, Ki Hwan Kim, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Hyun Park, Yu Jung Kim, Jin-Soo Kim, Jee Hyun Kim, Jin Won Kim
Summary: The study found that in the second-line treatment of biliary tract cancer, irinotecan/5-fluorouracil (mFOLFIRI) was not superior to oxaliplatin/5-fluorouracil (mFOLFOX), but both showed comparable efficacy and tolerability. Adverse events differed between the two treatment arms.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Pharmacology & Pharmacy
Qi Zhang, Ting Deng, Fen Yang, Weijian Guo, Dan Liu, Jiajia Yuan, Changsong Qi, Yanshuo Cao, Qiuqiong Yu, Huiming Cai, Zhi Peng, Xicheng Wang, Jun Zhou, Ming Lu, Jifang Gong, Jian Li, Yi Ba, Lin Shen
Summary: This study demonstrates that Simmitecan has a manageable safety profile as a single agent or as part of a combination therapy. The combination of Simmitecan and 5-FU/LV seems to have better efficacy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Physical
N. Ershadi, R. Safaiee, M. M. Golshan
Summary: This study investigates the electronic properties of metallic or semiconductive carbon nanotubes in combination with the anticancer drug 5-FU. It is found that chloromethylated (8,0) SWCNT releases the most energy and exhibits substantial magnetization, making it the most suitable carrier for 5-FU. The combination acts as a bipolar semiconductor and can be guided by both magnetic and electric fields.
APPLIED SURFACE SCIENCE
(2021)
Article
Pharmacology & Pharmacy
Buse Ardil, Mehlika Alper
Summary: This study aimed to investigate the effects of commercial Bru and Erio used in combination with the anticancer drug 5-FU on cell viability and apoptosis in human colorectal cancer cells. Results showed that Bru, alone or in combination with 5-FU, increased apoptosis in HT-29 cells compared to Erio. Additionally, combinations of Bru and 5-FU at IC50 concentrations led to an increase in bax and caspase-3 apoptotic genes.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
(2022)
Article
Gastroenterology & Hepatology
Shun Tezuka, Makoto Ueno, Satoshi Kobayashi, Tomomi Hamaguchi, Yui Yamachika, Ritsuko Oishi, Shuhei Nagashima, Taito Fukushima, Manabu Morimoto, Maeda Shin
Summary: This study compared the efficacy and safety of three different chemotherapy regimens for unresectable pancreatic cancer. The results showed that the modified FOLFIRINOX group and FOLFIRI group had longer overall survival, and the FOLFIRI group had a lower incidence of treatment-related adverse events. Therefore, modified FOLFIRINOX, FOLFIRI, and nal-IRI/5-FU/LV can all be considered as treatment options for second-line chemotherapy for unresectable pancreatic cancer.
Article
Biochemistry & Molecular Biology
C. Arnold Spek, Hella L. Aberson, JanWillem Duitman
Summary: This study identifies C/EBP delta as an important transcription factor driving macrophage-induced gemcitabine resistance in pancreatic cancer cells.
Article
Cell Biology
Xiaolei Gao, Xuan Zheng, Yixin Zhang, Liying Dong, Liangjie Sun, Na Zhao, Chong Ding, Zeyun Ma, Yixiang Wang
Summary: p53 mutations are common in colorectal carcinoma, promoting tumor malignancy and chemoresistance. The p53 mutations are associated with higher recurrence rates and larger tumors. The signaling pathway involving mutant p53, TCF21, and CD44 contributes to chemoresistance in colorectal carcinoma.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Hyun Min Ko, Wona Jee, Do-il Park, Kwan-Il Kim, Ji Hoon Jung, Hyeung-Jin Jang
Summary: The present study reveals that TA3 induces apoptosis in HCT116 colon cancer cells by inhibiting c-Myc expression, and enhances the apoptotic effects of doxorubicin and 5-FU. This finding provides insight into a potential mechanism for the development of new colon cancer therapies based on TA3.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Filippo Pietrantonio, Francesca Bergamo, Daniele Rossini, Filippo Ghelardi, Maria Caterina De Grandis, Marco Maria Germani, Giulia Barsotti, Vincenzo Formica, Giovanni Luca Frassineti, Giorgia Boscolo, Saverio Cinieri, Samantha Di Donato, Lorenzo Antonuzzo, Carlotta Antoniotti, Margherita Ambrosini, Vittoria Matilde Piva, Federico Nichetti, Matteo Fassan, Chiara Cremolini, Sara Lonardi
Summary: Upfront anti-EGFR therapy is the standard treatment for elderly patients with specific types of colorectal cancer. Comprehensive genomic profiling can help identify patients with resistance alterations, whose outcomes are worse compared to patients without these alterations.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Ophthalmology
Ayse Burcu Dirim, Ibrahim Cagri Tuerker, Ceylan Uslu Dogan, Selam Yekta Senduel, Emine Betuel Akbas Oezyuerek
Summary: This study compared the anatomical and functional success rates of external dacryocystorhinostomy (EX-DCR) with adjunctive 5-fluorouracil (5-FU) and silicone tube intubation in patients with primary acquired nasolacrimal duct obstruction. The results showed that both procedures were effective, with no significant difference in patency rates, recurrence rates, and improvement of tearing symptoms between the two groups.
JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Pharmacology & Pharmacy
Prangtip Uthaiwat, Aroonsri Priprem, Sirinart Chio-Srichan, Chatri Settasatian, Yao-Chang Lee, Pramote Mahakunakorn, Patcharee Boonsiri, Chanvit Leelayuwat, Patcharaporn Tippayawat, Ploenthip Puthongking, Jureerut Daduang
Summary: The study investigated the efficacy of melatonin niosome gel (MNG) and succinyl melatonin niosome gel (SNG) in treating 5-FU-induced small intestinal mucositis in mice. Both MNG and SNG maintained the normal integrity of the small intestines and protected against 5-FU-induced mucositis in mice.
